TrialAnnals of oncology : official journal of the European Society for Medical Oncology2013

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.

A M Evens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.